• LAM Therapeutics, of Guilford, Conn., closed an undisclosed Series A financing with private investors to its launch business operations. The company's mission is development of drugs for lymphangioleiomyomatosis (LAM), a rare lung disease. It will use the proceeds to identify clinical-stage drugs that might have activity against LAM and to begin clinical trials.

• Targovax AS, of Oslo, Norway, raised $3.6 million for development of its cancer vaccine pipeline, particularly TG01 for pancreatic cancer. The company said $2.3 million came from the Norwegian Research Council's BIA program, and $1.3 million came from existing and new investors, including the Radium Hospital Research Foundation, Algot Invest and Trygve Schiorbeck. Targovax's development program is based on targeting RAS mutations.